Results 171 to 180 of about 39,316 (219)
Post‐translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases
MedComm, Volume 7, Issue 4, April 2026.Posttranslational modifications (PTMs) serve as rapid and reversible molecular switches that reshape protein activity, stability, and interactomes, thereby governing virtually all physiological cues ranging from signal transduction to epigenetic memory. Mass spectrometry‐based proteomics has substantially expanded our understanding of PTM emergence and
Shuning Zhang +3 more
wiley +1 more source
Respirology Case Reports, Volume 14, Issue 4, April 2026.A patient with resectable NSCLC underwent neoadjuvant pembrolizumab‐based chemoimmunotherapy and lobectomy, which unexpectedly revealed extensive amyloid deposition in the lung and lymph nodes. LC–MS/MS identified AL (λ) amyloid, and hematologic workup confirmed an underlying λ‐restricted plasma cell neoplasm with t(11;14).
Weijie Ma +2 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 4, April 2026.Baseline heart‐type fatty acid binding protein (H‐FABP) independently predicts all‐cause mortality in patients with light chain cardiac amyloidosis (AL‐CA). Elevated H‐FABP levels (> 9.5 ng/mL) are associated with significantly worse survival and provide incremental prognostic value beyond established staging systems, improving risk stratification as ...
Xinqing Li +10 more
wiley +1 more source
European Journal of Haematology, Volume 116, Issue 4, Page 458-470, April 2026.Assessment of the comparative effectiveness and safety of three PI‐Rd triplets in relapsed/refractory multiple myeloma using data from the global, non‐interventional, observational INSIGHT‐MM study. ABSTRACT Objectives To assess the effectiveness/safety of three proteasome inhibitors (PIs), plus lenalidomide‐dexamethasone (Rd) triplet regimens, for the
Noemi Puig +18 more
wiley +1 more source
Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis [PDF]
, 2019 Lenihan, Daniel J +2 more
core +1 more source
European Journal of Neurology, Volume 33, Issue 4, April 2026.C5‐inhibition may represent an effective adjunctive treatment in therapy‐refractory myasthenic crisis, including thymoma‐associated MG (TAMG). ABSTRACT Introduction Generalized myasthenia gravis (gMG) may progress to life‐threatening myasthenic crises (MC) requiring mechanical ventilation.
Lea Gerischer +24 more
wiley +1 more source
Journal of Neurochemistry, Volume 170, Issue 4, April 2026.Cellular and molecular mechanisms contributing to TRPA1‐mediated mechanical and cold hypersensitivity and peripheral neuroinflammation in the reserpine‐induced experimental fibromyalgia model. (1) Macrophage‐originated reactive oxygen species (ROS; purple dots) target the transient receptor potential ankyrin 1 (TRPA1) channel localised in Schwann cells.
Evelyne Silva Brum +7 more
wiley +1 more source
Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets [PDF]
, 2018 et al,, Li, Shunqiang, Shao, Jieya
core +1 more source
Transfusion, Volume 66, Issue 4, Page 751-762, April 2026.Abstract Background High‐dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for fit patients with newly diagnosed multiple myeloma (MM). The increasing use of CD38 antibody‐based quadruplet induction regimens such as daratumumab‐VTd (Dara‐VTd) has raised concerns regarding impaired stem cell ...
Maximilian Alexander Röhnert +13 more
wiley +1 more source
Oral selinexor–dexamethasone for triple-class refractory multiple myeloma [PDF]
, 2019 al., et, Vij, Ravi
core +1 more source